AI cuts drug discovery time in half for longevity startups
Foundation models combining protein/DNA sequences with LLM embeddings predict transcription factor effects, explaining 50% of experimental variation in silico and enabling 2x faster discove…
Cryo and epigenetic reprogramming offer dual paths to extend healthy lifespan
Reversible cryopreservation could pause terminal illness until cures exist, while epigenetic reprogramming resets aged cells to youthful function; both approaches are approaching human-rele…
Rat kidney cryopreservation success paves way for human organ banking
Vitrification with nanoparticle rewarming achieved reversible rat kidney preservation; scaling to pig organs could eliminate transplant logistics bottlenecks and create a viable organ banki…
GLP-1 drugs join statins as proven longevity therapeutics
Health economics data shows GLP-1 agonists add 1-3 years of healthy life, comparable to statins, establishing a widely used longevity medicine class that could stack for further gains.
AI-driven deep phenotyping may shrink clinical trials and revive pharma productivity
High-content measurements and AI prediction could reduce patient numbers needed per trial, increasing throughput and potentially bending the cost curve of drug development (reversing Eroom'…
Virtual cell models require orders of magnitude more human trial data to predict toxicity
Current human drug trial data (~2,000 new drugs/year) is insufficient to train predictive toxicity models; decades needed unless data collection radically accelerates.